Mar. 25, 2024
RESEARCH TRIANGLE PARK, NORTH CAROLINA — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) has joined forces with Norgine, a prominent European pharmaceutical company, to bring PEDMARQSI® to the markets of Europe, Australia, and New Zealand. PEDMARQSI, the first and only approved therapy in the European Union (EU) and the United Kingdom (U.K.) designed to reduce the risk of cisplatin-induced hearing